Skip to content
Topics
Breast Cancer
Chronic Lymphocytic Leukemia
Melanoma
Multiple Myeloma
Non-small Cell Lung Cancer
Video Programs
ASCO GI 2026 Conference Coverage
ASH 2025 Conference Coverage
JADPRO 2025 Conference Coverage
Expert Perspectives in Multiple Myeloma
Expert Perspectives in NET
Expert Perspectives in RCC
Patient Programs
Treatment Perspectives in Multiple Myeloma
Dialogues in Multiple Myeloma
About
About Oncology Matrix
Advertise
Contact Us
Topics
Breast Cancer
Chronic Lymphocytic Leukemia
Melanoma
Multiple Myeloma
Non-small Cell Lung Cancer
Video Programs
ASCO GI 2026 Conference Coverage
ASH 2025 Conference Coverage
JADPRO 2025 Conference Coverage
Expert Perspectives in Multiple Myeloma
Expert Perspectives in NET
Expert Perspectives in RCC
Patient Programs
Treatment Perspectives in Multiple Myeloma
Dialogues in Multiple Myeloma
About
About Oncology Matrix
Advertise
Contact Us
Subscribe
Hagen Kennecke, MD, MHA, FRCPC: Cabozantinib as a Treatment Option Following Progression in NET
December 9, 2025
Dr. Hagen Kennecke discusses the use of cabozantinib in the treatment of patients with NET who progressed on prior therapies.
MORE EXPERT PERSPECTIVES IN NET:
Hagen Kennecke, MD, MHA, FRCPC: Benefit of Cabozantinib in Patients with Advanced Neuroendocrine Tumors
Hagen Kennecke, a medical oncologist and professor of medicine at Oregon Health Sciences University, discusses the efficacy of cabozantinib in patients with advanced neuroendocrine tumors, specifically in relation to progression-free survival.
Play
Neena Vijayvergia, MD: Importance of Patient Education for Treating Neuroendocrine Tumors
Dr. Vijayvergia emphasizes the importance of patient-physician communication and patient education when treating neuroendocrine tumors.
Play
